390 related articles for article (PubMed ID: 12558910)
21. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
Dogan UB; Atabay A; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
23. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
24. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
[TBL] [Abstract][Full Text] [Related]
25. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
26. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
Akhan SC; Kalender B; Ruzgar M
Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Deltenre P; Corouge M; Canva V; Castel H; Wartel F; Dharancy S; Louvet A; Lazrek M; Moreno C; Henrion J; Mathurin P
J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
[TBL] [Abstract][Full Text] [Related]
30. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
Hsu CS; Hsu SJ; Chen HC; Tseng TC; Liu CH; Niu WF; Jeng J; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3719-24. PubMed ID: 21321200
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
32. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
35. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
[TBL] [Abstract][Full Text] [Related]
36. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
[TBL] [Abstract][Full Text] [Related]
38. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
39. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
40. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
